Results 21 to 30 of about 5,507 (191)

Bioavailability of dihydroergotamine. [PDF]

BMJ, 1980
J Kanto
openalex   +4 more sources

New Approaches to Shifting the Migraine Treatment Paradigm

Frontiers in Pain Research, 2022
The standard of care paradigm for migraine treatment has been based almost exclusively on approaches that grew out of the happenstance use of market pharmaceuticals.
Brian Johnson, Frederick G. Freitag
doaj   +1 more source

Dihydroergotamine ameliorates liver fibrosis by targeting transforming growth factor β type II receptor. [PDF]

World J Gastroenterol, 2023
Zheng KX, Yuan SL, Dong M, Zhang HL, Jiang XX, Yan CL, Ye RC, Zhou HQ, Chen L, Jiang R, Cheng ZY, Zhang Z, Wang Q, Jin WZ, Xie W.   +14 more
europepmc   +2 more sources

Machine-learning-based virtual screening and ligand docking identify potent HIV-1 protease inhibitors

Artificial Intelligence Chemistry, 2023
The human immunodeficiency virus type 1 (HIV-1) is a retrovirus that can cause acquired immunodeficiency syndrome (AIDS), severely weakening the immune system. The United Nations estimates that there are 37.7 million people with HIV worldwide.
Andrew K. Gao, Trevor B. Chen, Valentina L. Kouznetsova, Igor F. Tsigelny   +3 more
doaj   +1 more source

Chronic Migraine: A Narrative Review on the Use of Botulinum Toxin with Clinical Indications and Future Directions

Journal of Integrative Neuroscience, 2022
Chronic migraine belongs to the “chronic long-duration headaches”, and it is associated to high burden and significant economic impact. Treatment for both episodic (EM) and chronic migraine (CM) is based on the management of acute attacks and their ...
Loredana Raciti, Gianfranco Raciti, David Militi, Carmela Casella, Rocco Salvatore Calabrò   +4 more
doaj   +1 more source

Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure

The Journal of Headache and Pain, 2022
Background Headache recurrence is a common feature of acute therapies, whether approved or still in development, and continues to be a significant problem for both the patient and the clinician.
Stewart J. Tepper, Jessica Ailani, Sutapa Ray, Joe Hirman, Stephen B. Shrewsbury, Sheena K. Aurora   +5 more
doaj   +1 more source

Dihydroergotamine Increases Histamine Brain Levels and Improves Memory in a Scopolamine-Induced Amnesia Model. [PDF]

Int J Mol Sci
Hernández-Rodríguez M, Mera Jiménez E, Nicolás-Vázquez MI, Miranda-Ruvalcaba R.   +3 more
europepmc   +3 more sources

Correction to “Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV‑2 Infection” [PDF]

ACS Omega
Soledad Stagnoli, Gabriele Macari, Pietro Corsi, Barbara Capone, Ander Vidaurrazaga, June Ereño-Orbea, Ana Ardá, Fabio Polticelli, Jesus Jimenez-Barbero, Nicola GA Abrescia, Ivan Coluzza   +10 more
doaj   +2 more sources

CSF Circulation and Congenital Hydrocephalus

Pediatric Neurology Briefs, 1997
A new model of the cerebrospinal fluid (CSF) circulation, involving brain capillaries as the main site of CSF absorption, is proposed from the Karolinska MR Research Center and Department of Neuroradiology, Karolinska Hospital, Stockholm, Sweden.
J Gordon Millichap
doaj   +1 more source

Short Term Oral Methylergonovine Maleate Prophylaxis for Status Migrainosus. Case Series and Review of Literature

Frontiers in Neurology, 2019
Background: Intravenous dihydroergotamine (DHE) is frequently used during inpatient hospitalizations or outpatient infusion therapies for 3–5 days in order to break the continuous cycle of status migrainosus.
Najiya Haque, Nauman Tariq
doaj   +1 more source